<DOC>
	<DOCNO>NCT00080756</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . Deslorelin combine low-dose add-back estradiol testosterone ( give replace hormone suppress deslorelin ) may effective prevent breast cancer at-risk woman . PURPOSE : This phase II trial study well give deslorelin together estradiol testosterone work prevent breast cancer premenopausal woman high risk disease .</brief_summary>
	<brief_title>Deslorelin Combined With Low-Dose Add-Back Estradiol Testosterone Preventing Breast Cancer Premenopausal Women Who Are High Risk This Disease</brief_title>
	<detailed_description>OBJECTIVES : I. Assess effect breast treatment gonadotropin-releasing hormone agonist ( GnRHA ) -based regimen breast cancer ( BRCA ) gene mutation carrier , include correlation change mammographic magnetic resonance imaging ( MRI ) densities tissue morphometrics biomarkers . II . Evaluate perspectives risk reduction option impact quality-of-life ( QOL ) measure participation chemopreventive protocol risk reduction surgery . OUTLINE : GROUP 1 : Patients receive deslorelin , estradiol , testosterone intranasally daily ( QD ) 6 month . Patients undergo plan risk reduction mastectomy . GROUP 2 : Patients receive deslorelin , estradiol , testosterone intranasally QD 10 month . Patients undergo continue surveillance 10 month . After completion study treatment , patient follow every 6 month 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<criteria>Patients must generally good health lab value physical examination within normal limit Known high risk breast cancer due BRCA mutation empiric risk &gt; 30 % lifetime Claus model No evidence history pervious cancer , except nonmelanoma skin cancer Premenopausal woman plan risk reduction mastectomy 6 month ( Group 1 ) continue surveillance ( Group 2 ) Prior tubal ligation willing use nonhormonal barrier method contraception Signed Informed Consent Form document study accordance Federal , State Institutional regulation Must current nonsmoker GnRHA treatment within 12 month study entry Nasal polyposis , atrophic rhinitis , severe allergic vasomotor rhinitis , sinusitis require current treatment treatment 3 month previous year Concurrent medication include : corticosteroid ( prednisone , prednisolone , cortisone acetate , Decadron , Deltasone , hydrocortisone , Hydrocortone , Medrol ) , estrogens , progestins androgen , include oral , implanted , injected contraceptive ; ( At least 6 month must elapse since last use implant injected contraceptive Norplant ) Pregnant breastfeed last six month Immeasurable breast density mammogram</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>BRCA1 mutation carrier</keyword>
	<keyword>BRCA2 mutation carrier</keyword>
</DOC>